Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma

K. Miyahara, K. Nouso, Y. Morimoto, Y. Takeuchi, H. Hagihara, K. Kuwaki, H. Onishi, F. Ikeda, Y. Miyake, S. Nakamura, H. Shiraha, A. Takaki, M. Honda, S. Kaneko, T. Sato, S. Sato, S. Obi, S. Iwadou, Y. Kobayashi, K. TakaguchiK. Kariyama, Y. Takuma, H. Takabatake, K. Yamamoto, Kazuhide Yamamoto, Yuki Morimoro, Yoshitaka Takuma, Hiroyuki Takabatake, Shin Ichi Fujioka, Toshiya Osawa, Kazuya Kariyama, Junichi Toshimori, Haruhiko Kobashi, Hirokazu Miyatake, Shuji Uematsu, Ryoichi Okamoto, Yasuyuki Araki, Masafumi Tatsukawa, Kazuhisa Yabushita, Toshinari Shimoe, Kohsaku Sakaguchi, Tatsuro Sakata, Toshihiko Kaneyoshi, Manabi Miyashita, Yasuhiro Makino, Akio Moriya, Masaharu Ando, Nobuyuki Baba, Tomonori Seno, Takuya Nagano, Eiji Matsumoto, Hiroki Takayama

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background:We previously reported that expressions of the pro-angiogenic cytokines angiopoietin-2 (Ang-2), follistatin, granulocyte colony-stimulating factor, hepatocyte growth factor, leptin, platelet-derived growth factor-BB, platelet endothelial cell adhesion molecule-1, and vascular endothelial growth factor were associated with the response to sorafenib in patients with advanced hepatocellular carcinoma (HCC). The aim of the present study is to examine the same relationship in a larger cohort.Methods:In the current retrospective cohort study, we measured serum levels of the eightcytokines in 120 consecutive HCC patients who were treated with sorafenib. We evaluated the effects of increased expression of serum cytokines on progression-free survival (PFS) and overall survival (OS).Results:Elevated expression of Ang-2 correlated both with significantly shorter PFS (hazard ratio (HR), 1.84; 95% confidence interval (CI), 1.21-2.81), and OS (HR, 1.95; 95% CI, 1.21-3.17). Patients with more than three cytokines expressed above the median similarly had significantly shorter PFS (HR, 1.98; 95% CI, 1.30-3.06) and OS (HR, 1.94; 95% CI, 1.19-3.22). Differences in OS were evident in cases with the evidence of macroscopic vascular invasion or extrahepatic metastasis.Conclusion:High expression of Ang-2 or more than cytokines in serum is associated with poor PFS and OS in HCC patients treated with sorafenib.

Original languageEnglish
Pages (from-to)2072-2078
Number of pages7
JournalBritish Journal of Cancer
Volume109
Issue number8
DOIs
Publication statusPublished - Oct 15 2013

Keywords

  • angiogenesis
  • angiopoietin-2
  • cytokine
  • hepatocellular carcinoma
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Miyahara, K., Nouso, K., Morimoto, Y., Takeuchi, Y., Hagihara, H., Kuwaki, K., Onishi, H., Ikeda, F., Miyake, Y., Nakamura, S., Shiraha, H., Takaki, A., Honda, M., Kaneko, S., Sato, T., Sato, S., Obi, S., Iwadou, S., Kobayashi, Y., ... Takayama, H. (2013). Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 109(8), 2072-2078. https://doi.org/10.1038/bjc.2013.554